

114TH CONGRESS  
1ST SESSION

# H. R. 3677

To reduce opioid misuse and abuse.

---

## IN THE HOUSE OF REPRESENTATIVES

OCTOBER 1, 2015

Mr. FOSTER (for himself, Ms. EDWARDS, Ms. ESTY, and Mr. SEAN PATRICK MALONEY of New York) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To reduce opioid misuse and abuse.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Opioid Abuse Preven-  
5       tion and Treatment Act of 2015”.

6       **SEC. 2. PILOT PROJECT.**

7       (a) IN GENERAL.—The Secretary of Health and  
8       Human Services (referred to in this Act as the “Sec-  
9       retary”) shall award grants to one or more States to carry  
10      out a 1-year pilot project to develop a standardized peer  
11      review process and methodology to review and evaluate

1 prescribing and pharmacy dispensing patterns, through a  
2 review of prescription drug monitoring programs (referred  
3 to in this section as “PDMP”) in the States receiving such  
4 grants.

5 (b) METHODOLOGY.—The recipients of a grant under  
6 this section shall develop a systematic, standardized meth-  
7 odology to identify and investigate questionable or inap-  
8 propiate prescribing and dispensing patterns of sub-  
9 stances on schedule II or III under section 202 of the Con-  
10 trolled Substances Act (21 U.S.C. 812). Such peer review  
11 methodology and prescribing and dispensing patterns shall  
12 be shared with the appropriate State regulators and health  
13 profession boards.

14 (c) REQUIREMENTS.—A State receiving a grant  
15 under this section—

16 (1) with respect to controlled substances for  
17 which a prescriber is required to be registered with  
18 by the Drug Enforcement Administration in order to  
19 prescribe such controlled substances, shall make the  
20 information with respect to such controlled sub-  
21 stances from the PDMP available to State regu-  
22 lators and licensing boards; and

23 (2) with respect to any other controlled sub-  
24 stances, may make the information with respect to

1 such controlled substances from the PDMP available  
2 to State regulators and licensing boards.

3 (d) SUBGRANTEES.—A quality improvement organi-  
4 zation with which the Secretary has entered into a con-  
5 tract under part B of title XI of the Social Security Act  
6 (42 U.S.C. 1320c et seq.) may serve as the subgrantee  
7 under this subsection to develop peer review processes as  
8 described in subsection (a).

9 **SEC. 3. PRESCRIPTION DRUG, HEROIN, AND OTHER CON-**

10 **TROLLED SUBSTANCE ABUSE PREVENTION.**

11 Part P of title III of the Public Health Service Act  
12 (42 U.S.C. 280g) is amended by adding at the end the  
13 following:

14 **“SEC. 399V–6. PRESCRIPTION DRUG, HEROIN, AND OTHER**  
15 **CONTROLLED SUBSTANCE ABUSE PREVEN-**  
16 **TION.**

17 “(a) TRAINING GRANTS.—

18 “(1) IN GENERAL.—The Secretary shall award  
19 5-year grants to eligible entities to facilitate training  
20 in order to increase the capacity of health care pro-  
21 viders to conduct patient screening, brief interven-  
22 tions, and referral to treatment as needed, such as  
23 in health care settings to prevent the abuse of pre-  
24 scription drugs, heroin, and other controlled sub-  
25 stances. The grant program under this section may

1       be coordinated with the Screening Brief Intervention  
2       and Referral to Treatment grant program of the  
3       Substance Abuse and Mental Health Services Ad-  
4       ministration, or other appropriate programs.

5               “(2) ELIGIBLE ENTITIES.—In this subsection,  
6       the term ‘eligible entity’ includes—

7                       “(A) States;

8                       “(B) physician organizations;

9                       “(C) continuing education entities, such as  
10       health profession boards or health accrediting  
11       bodies;

12                       “(D) peer recovery organizations; and

13                       “(E) other appropriate health or profes-  
14       sional education organizations or institutions.

15               “(b) EXPANSION OF PRESCRIBING AUTHORITY.—  
16       The Secretary, acting through the Administrator of the  
17       Health Resources and Services Administration, shall  
18       award grants to States for the purpose of evaluating the  
19       prospect of the health professions board of such States  
20       reviewing and expanding prescribing authorities of pro-  
21       viders, such as advance practice nurses and physician’s as-  
22       sistants, with respect to prescribing drugs for the treat-  
23       ment of the abuse of prescription drugs, heroin, or other  
24       controlled substances.”.

1   **SEC. 4. PRESCRIPTION DRUG ABUSE TRAINING AND**  
2                   **SCREENING PROGRAMS.**

3       (a) CONTINUING EDUCATION GRANTS.—The Sec-  
4     retary shall award grants to States to develop continuing  
5     education criteria and review processes that allow State  
6     health profession boards or State agencies to certify ap-  
7     propriate education and training for informed and safe  
8     prescribing of opioids and other drugs listed on schedule  
9     II or III under section 202 of the Controlled Substances  
10   Act (21 U.S.C. 812).

11     (b) SCREENING PROGRAM.—The Attorney General  
12   shall request that a practitioner registered under section  
13   303(f) of the Controlled Substances Act (21 U.S.C.  
14   823(f)) conduct patient screening for potential drug mis-  
15   use or abuse before prescribing a drug listed on schedule  
16   II or III under section 202 of the Controlled Substances  
17   Act (21 U.S.C. 812), according to standards established  
18   by the applicable State licensing body.

19   **SEC. 5. FDA REVIEW OF NALOXONE.**

20     The Secretary, acting through the Commissioner of  
21   Food and Drugs, shall conduct a review of naloxone to  
22   consider whether naloxone should cease to be subject to  
23   section 503(b) of the Federal Food, Drug, and Cosmetic  
24   Act (21 U.S.C. 353(b)) and be available as an over-the-  
25   counter drug, in order to increase access to such drug.

1   **SEC. 6. PRESCRIPTION DRUG DISPOSAL.**

2       The Secretary shall convene or coordinate with an ex-  
3 isting entity an interagency working group—

4           (1) to encourage States and local governments  
5       to increase opportunities for disposal of opiates, such  
6       as frequent “take-back programs” and fixed medi-  
7       cine disposal sites at law enforcement public build-  
8       ings; and

9           (2) to reduce opportunities for abuse of opiates,  
10      such as establishing opioid dispensing limits at hos-  
11      pital emergency departments.

12   **SEC. 7. GAO REPORT.**

13      The Comptroller General of the United States shall—

14           (1) review opioid abuse programs, heroin abuse  
15       programs, and policies in Federal agencies and best  
16       practices with respect to opioid and heroin abuse  
17       and overdose programs of the States; and

18           (2) not later than 18 months after the date of  
19       enactment of this Act, issue a report to Congress on  
20       its findings and recommendations on ways to reduce  
21       opioid and heroin abuse and overdoses.

